Oura expects close to $2 billion in 2026 sales, almost doubling for the second consecutive year

The CEO of Finland-based Oura shared ambitious sales projections with CNBC, anticipating close to $2 billion in revenue for the wearable technology firm in 2026. This optimistic forecast comes in the wake of the company's substantial $900 million funding round in October, as Oura focuses on leveraging artificial intelligence and expanding its international presence. According to CEO Tom Hale, Oura is on track to achieve $1 billion in sales by 2025, effectively doubling its revenue from 2024. In an exclusive interview at the Web Summit in Lisbon, Hale expressed confidence in the upcoming year, stating, "Next year is certainly going to be a lot more. I don't know if we know exactly how much, but it'll be north, maybe close to $2 billion." This revised outlook marks a significant increase from a previously estimated $1.5 billion in sales, positioning Oura for a remarkable consecutive year of growth. Hale noted the company’s success in the market, particularly with health features tailored for women, and its push into international markets, both of which are crucial drivers of their expansion. Since launching the Oura Ring in 2015, the Finnish company has sold over 5.5 million units, with more than 2.5 million sold since June 2024. Oura's valuation currently stands at $11 billion. Hale emphasized that Oura has always been focused on AI, and he is particularly excited about the potential of AI to enhance preventative healthcare features in the future. "One of the things that Oura does particularly well is generate insights—basically text—that help you understand your metrics," Hale explained. The company employs AI to convert data into actionable advice and coaching for users. Additionally, Oura has introduced a chatbot, known as Oura Advisor, which functions as a personal health assistant. In 2022, Oura partnered with Natural Cycles, an FDA-approved birth control app, to incorporate fertility tracking features. Earlier this year, the company also launched glucose monitoring through a collaboration with Dexcom and announced research into blood pressure monitoring in October. Hale envisions Oura as a "guardian angel" for users, providing predictions about their long-term health. Despite these ambitious plans, he clarified that there are currently no updates regarding a potential IPO.